[The clinical efficacy and outlook for the use of new drugs for metabolic therapy in dermatology].
Based on the literature data and their own findings, the authors give grounds for the use of phosphaden, riboxin, and dipromonium in psoriasis, eczema, and atrophic lichen. Prospects in the application of vitamin synthetic analogues and of coenzymic preparations are shown.
Kubanova
A A
AA
Khamaganova
I V
IV
D000249:Adenosine Monophosphate / Q000627:therapeutic use*; D000328:Adult; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004734:Energy Metabolism / Q000187:drug effects; D005260:Female; D006801:Humans; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D007292:Inosine Nucleotides / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy* / Q000378:metabolism
D003879:Dermatologic Agents; D007292:Inosine Nucleotides; D000644:Quaternary Ammonium Compounds; D000249:Adenosine Monophosphate; C001002:diisopropylamine dichloroacetate; D007290:Inosine Diphosphate
Klinicheskaia éffektivnost' i perspektivy primeneniia nekotorykh novykh sredstv metabolicheskoĭ terapii v dermatologii.